

## PHARMACEUTICAL SYSTEM


## IN OUT-PATIENT SECTOR

### PRICING IN THE OUT-PATIENT SECTOR IN SLOVENIA

### REIMBURSEMENT IN THE OUT-PATIENT SECTOR

<b>Legal basis:</b>	<ul style="list-style-type: none"> <li>• Medicinal Products Act</li> <li>• Rules on price setting for medicinal products for human use</li> </ul>
<b>Responsible institution:</b>	<ul style="list-style-type: none"> <li>• Agency for Medicinal Products and Medical Devices</li> </ul>
<b>Prices are set for:</b>	<ul style="list-style-type: none"> <li>• Prescription medicinal products, financed or intending for financing from public funds</li> <li>• Harmonization of prices twice yearly</li> <li>• Number of prices set for out-patient sector: 2.600</li> <li>• Total number of prices set: 3.700</li> </ul>
<b>International price comparison</b>	<ul style="list-style-type: none"> <li>• Reference countries: Austria, France, Germany</li> <li>• Ex-factory prices are used for calculations</li> </ul>

<b>Legal basis:</b>	<ul style="list-style-type: none"> <li>• Health Care and Health Insurance Act</li> <li>• Rules on classification of medicinal products for human use on the lists</li> </ul>
<b>Responsible institution:</b>	<ul style="list-style-type: none"> <li>• Health Insurance Institute</li> </ul>
<b>Type of lists: POSITIVE INTERMEDIATE NEGATIVE</b>	<ul style="list-style-type: none"> <li>• Medicines classified on lists: prescription medicinal products, products prepared in pharmacy</li> <li>• Reimbursable lists: positive, intermediate</li> <li>• Decision of the Committee - measures I</li> <li>• Number of medicines on positive list: 1.550</li> <li>• Number of medicines on intermediate list: 550</li> </ul>
<b>Level of reimbursement:</b>	<ul style="list-style-type: none"> <li>• <b>POSITIVE LIST:</b> 100% or 75% , the rest is paid by voluntary health insurance or by patient</li> <li>• <b>INTERMEDIATE LIST:</b> 10%, the rest is paid by voluntary health insurance or by patient</li> <li>• <b>EXEMPTIONS:</b> vulnerable groups – children, young people in education, patients with certain diseases: 100% reimbursement for positive list</li> </ul>



**Reforms – planned:**

*Lowering of % used for price setting*  
*Change of calculations for off-patent medicines*

<b>Setting of higher prices</b>	<ul style="list-style-type: none"> <li>• For medicines with high therapeutic value, to prevent withdrawal</li> <li>• Decision of Pricing Committee - measures I</li> <li>• Number of higher prices set for out-patient sector: 110</li> <li>• Total number of higher prices set: 135</li> </ul>
<b>Price structure:</b>	<ul style="list-style-type: none"> <li>• PRICE= ex-factory + wholesale margin + pharmacy margin + VAT</li> <li>• Wholesale margin: % of ex-factory price, 6 classes 10% - 2%, max = 30 €</li> <li>• Pharmacy margin: fixed amount, negotiated with Health Insurance, min = 1,40 €/prescription</li> <li>• VAT: 8,5%, applies to wholesale price and pharmacy margin</li> </ul>
<b>Price negotiations:</b>	<ul style="list-style-type: none"> <li>• Negotiations with Health Insurance Institute</li> <li>• Number of negotiated prices: 1.200</li> </ul>

### REFERENCE PRICE SYSTEM

